Chugai Pharmaceutical (OTCMKTS:CHGCY) Shares Gap Down – Here’s Why

Posted by Defense World Staff on Mar 8th, 2026

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY – Get Free Report) gapped down before the market opened on Friday . The stock had previously closed at $30.75, but opened at $28.97. Chugai Pharmaceutical shares last traded at $29.98, with a volume of 8,901 shares changing hands.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on CHGCY shares. Smbc Nikko Sec. upgraded shares of Chugai Pharmaceutical to a “strong-buy” rating in a report on Wednesday, February 25th. UBS Group raised shares of Chugai Pharmaceutical to a “strong-buy” rating in a report on Tuesday, January 27th. Two analysts have rated the stock with a Strong Buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Strong Buy”.

Check Out Our Latest Analysis on CHGCY

Chugai Pharmaceutical Trading Down 2.8%

The stock’s 50 day moving average price is $28.75 and its 200 day moving average price is $25.78. The company has a market capitalization of $98.40 billion, a price-to-earnings ratio of 34.37 and a beta of 0.60.

Chugai Pharmaceutical (OTCMKTS:CHGCY – Get Free Report) last announced its quarterly earnings data on Thursday, January 29th. The company reported $0.25 EPS for the quarter. The company had revenue of $2.25 billion during the quarter. Chugai Pharmaceutical had a net margin of 34.47% and a return on equity of 22.00%. On average, research analysts expect that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.74 earnings per share for the current year.

About Chugai Pharmaceutical

(Get Free Report)

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.